

Yukari C Manabe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1734316/publications.pdf>

Version: 2024-02-01

128
papers

3,961
citations

172457

29
h-index

161849

54
g-index

147
all docs

147
docs citations

147
times ranked

6283
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of COVID-19 pandemic on technologic and process innovation in point-of-care diagnostics for sexually transmitted infections. <i>Clinical Biochemistry</i> , 2023, 117, 75-83.	1.9	1
2	Telemedicine and visit completion among people with HIV during the coronavirus disease 2019 pandemic compared with prepandemic. <i>Aids</i> , 2022, 36, 355-362.	2.2	18
3	Supporting Women's Leadership Development in Global Health through Virtual Events and Near-Peer Networking. <i>Annals of Global Health</i> , 2022, 88, 2.	2.0	7
4	Preclinical Validation of a Novel Injection-Molded Swab for the Molecular Assay Detection of SARS-CoV-2. <i>Diagnostics</i> , 2022, 12, 206.	2.6	3
5	Differentiation of Individuals Previously Infected with and Vaccinated for SARS-CoV-2 in an Inner-City Emergency Department. <i>Journal of Clinical Microbiology</i> , 2022, 60, jcm0239021.	3.9	5
6	Improving the specificity of nucleic acid detection with endonuclease-actuated degradation. <i>Communications Biology</i> , 2022, 5, 290.	4.4	3
7	Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Seroprevalence in Decedents Undergoing Forensic Postmortem Examination: Feasibility for Real-Time Pandemic Surveillance. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac142.	0.9	0
8	Longitudinal Analysis of SARS-CoV-2 Vaccine Breakthrough Infections Reveals Limited Infectious Virus Shedding and Restricted Tissue Distribution. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	36
9	Retrospective Analysis of Ugandan Men with Urethritis Reveals <i>Mycoplasma genitalium</i> and Associated Macrolide Resistance. <i>Microbiology Spectrum</i> , 2022, , e0230421.	3.0	5
10	Daily longitudinal sampling of SARS-CoV-2 infection reveals substantial heterogeneity in infectiousness. <i>Nature Microbiology</i> , 2022, 7, 640-652.	13.3	99
11	High burden of untreated syphilis, drug resistant <i>Neisseria gonorrhoeae</i> , and other sexually transmitted infections in men with urethral discharge syndrome in Kampala, Uganda. <i>BMC Infectious Diseases</i> , 2022, 22, 440.	2.9	6
12	Respiratory viruses in rural Zambia before and during the COVID-19 pandemic. <i>Tropical Medicine and International Health</i> , 2022, 27, 647-654.	2.3	10
13	Evaluation of Four Point of Care (POC) Antigen Assays for the Detection of the SARS-CoV-2 Variant Omicron. <i>Microbiology Spectrum</i> , 2022, 10, .	3.0	15
14	Mitigation of SARS-CoV-2 transmission at a large public university. <i>Nature Communications</i> , 2022, 13, .	12.8	21
15	Limitations of Molecular and Antigen Test Performance for SARS-CoV-2 in Symptomatic and Asymptomatic COVID-19 Contacts. <i>Journal of Clinical Microbiology</i> , 2022, 60, .	3.9	13
16	High Sensitivity and NPV for BinaxNOW Rapid Antigen Test in Children at a Mass Testing Site during Prevalent Delta Variant Period. <i>Microbiology Spectrum</i> , 2022, 10, .	3.0	7
17	High Burden of Bloodstream Infections Associated With Antimicrobial Resistance and Mortality in the Neonatal Intensive Care Unit in Pune, India. <i>Clinical Infectious Diseases</i> , 2021, 73, 271-280.	5.8	23
18	Evaluation of Serological SARS-CoV-2 Lateral Flow Assays for Rapid Point-of-Care Testing. <i>Journal of Clinical Microbiology</i> , 2021, 59, .	3.9	46

#	ARTICLE	IF	CITATIONS
19	Chest X-ray interpretation does not complement Xpert MTB/RIF in diagnosis of smear-negative pulmonary tuberculosis among TB-HIV co-infected adults in a resource-limited setting. <i>BMC Infectious Diseases</i> , 2021, 21, 63.	2.9	8
20	Antigen-Based Testing but Not Real-Time Polymerase Chain Reaction Correlates With Severe Acute Respiratory Syndrome Coronavirus 2 Viral Culture. <i>Clinical Infectious Diseases</i> , 2021, 73, e2861-e2866.	5.8	217
21	Urine Lipoarabinomannan Testing in Adults With Advanced Human Immunodeficiency Virus in a Trial of Empiric Tuberculosis Therapy. <i>Clinical Infectious Diseases</i> , 2021, 73, e870-e877.	5.8	4
22	Clustering of SARS-CoV-2 Infections in Households of Patients Diagnosed in the Outpatient Setting in Baltimore, Maryland. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab121.	0.9	5
23	Future potential of Rapid Acceleration of Diagnostics (RADx Tech) in molecular diagnostics. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 251-253.	3.1	4
24	Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis. <i>Aids</i> , 2021, 35, 1585-1595.	2.2	10
25	Delayed Rise of Oral Fluid Antibodies, Elevated BMI, and Absence of Early Fever Correlate With Longer Time to SARS-CoV-2 RNA Clearance in a Longitudinally Sampled Cohort of COVID-19 Outpatients. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab195.	0.9	13
26	Durable SARS-CoV-2 B cell immunity after mild or severe disease. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	76
27	A portable magnetofluidic platform for detecting sexually transmitted infections and antimicrobial susceptibility. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	41
28	A Narrative Review of Where We Are With Point-of-Care Sexually Transmitted Infection Testing in the United States. <i>Sexually Transmitted Diseases</i> , 2021, 48, S71-S77.	1.7	22
29	Baseline Xpert MTB/RIF ct values predict sputum conversion during the intensive phase of anti-TB treatment in HIV infected patients in Kampala, Uganda: a retrospective study. <i>BMC Infectious Diseases</i> , 2021, 21, 513.	2.9	4
30	Longitudinal Assessment of Diagnostic Test Performance Over the Course of Acute SARS-CoV-2 Infection. <i>Journal of Infectious Diseases</i> , 2021, 224, 976-982.	4.0	119
31	Salmonella Bloodstream Infections in Hospitalized Children with Acute Febrile Illness—Uganda, 2016–2019. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 105, 37-46.	1.4	12
32	Antigen-based Rapid Diagnostic Testing or Alternatives for Diagnosis of Symptomatic COVID-19. <i>Epidemiology</i> , 2021, 32, 811-819.	2.7	11
33	Pregnancy alters interleukin-1 beta expression and antiviral antibody responses during severe acute respiratory syndrome coronavirus 2 infection. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 301.e1-301.e14.	1.3	27
34	The Clinical Course of COVID-19 in the Outpatient Setting: A Prospective Cohort Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab007.	0.9	55
35	Self-Collected Oral Fluid Saliva Is Insensitive Compared With Nasal-Oropharyngeal Swabs in the Detection of Severe Acute Respiratory Syndrome Coronavirus 2 in Outpatients. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa648.	0.9	17
36	Implementation of a standardised and quality-assured enhanced gonococcal antimicrobial surveillance programme in accordance with WHO protocols in Kampala, Uganda. <i>Sexually Transmitted Infections</i> , 2021, 97, 312-316.	1.9	15

#	ARTICLE	IF	CITATIONS
37	Factors that Influence the Reported Sensitivity of Rapid Antigen Testing for SARS-CoV-2. <i>Frontiers in Microbiology</i> , 2021, 12, 714242.	3.5	51
38	Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Status in Decedents Undergoing Forensic Postmortem Examination in Maryland, May 24 to June 30, 2020. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa611.	0.9	1
39	Implementation and Accuracy of BinaxNOW Rapid Antigen COVID-19 Test in Asymptomatic and Symptomatic Populations in a High-Volume Self-Referred Testing Site. <i>Microbiology Spectrum</i> , 2021, 9, e0100821.	3.0	20
40	Implementation of the Comprehensive Unit-Based Safety Program to Improve Infection Prevention and Control Practices in Four Neonatal Intensive Care Units in Pune, India. <i>Frontiers in Pediatrics</i> , 2021, 9, 794637.	1.9	6
41	Change in Plasma Cryptococcal Antigen Titer Is Not Associated With Survival Among Human Immunodeficiency Virus-infected Persons Receiving Preemptive Therapy for Asymptomatic Cryptococcal Antigenemia. <i>Clinical Infectious Diseases</i> , 2020, 70, 353-355.	5.8	3
42	Multicenter Study of the Accuracy of the BD MAX Multidrug-resistant Tuberculosis Assay for Detection of Mycobacterium tuberculosis Complex and Mutations Associated With Resistance to Rifampin and Isoniazid. <i>Clinical Infectious Diseases</i> , 2020, 71, 1161-1167.	5.8	29
43	Empirical tuberculosis therapy in advanced HIV disease. <i>Lancet HIV</i> , 2020, 7, e3-e5.	4.7	1
44	A Parsimonious Host Inflammatory Biomarker Signature Predicts Incident Tuberculosis and Mortality in Advanced Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2020, 71, 2645-2654.	5.8	11
45	Reduction in Baseline CD4 Count Testing Following Human Immunodeficiency Virus "Treat All" Adoption in Uganda. <i>Clinical Infectious Diseases</i> , 2020, 71, 2497-2499.	5.8	6
46	The Need for More and Better Testing for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 2153.	7.4	84
47	Patient and health system factors associated with pretreatment loss to follow up among patients diagnosed with tuberculosis using XpertA® MTB/RIF testing in Uganda. <i>BMC Public Health</i> , 2020, 20, 1855.	2.9	4
48	Comparison of the analytical sensitivity of seven commonly used commercial SARS-CoV-2 automated molecular assays. <i>Journal of Clinical Virology</i> , 2020, 130, 104578.	3.1	70
49	COVID-19 Serology at Population Scale: SARS-CoV-2-Specific Antibody Responses in Saliva. <i>Journal of Clinical Microbiology</i> , 2020, 59, .	3.9	193
50	Overcoming Challenges With the Adoption of Point-of-Care Testing. <i>Point of Care</i> , 2020, 19, 77-83.	0.4	17
51	Leadership training to accelerate progress in public health in sub-Saharan Africa: time for action. <i>The Lancet Global Health</i> , 2020, 8, e1253-e1254.	6.3	3
52	Functional adrenal insufficiency among tuberculosis-human immunodeficiency virus co-infected patients: a cross-sectional study in Uganda. <i>BMC Research Notes</i> , 2020, 13, 224.	1.4	1
53	Low male partner attendance after syphilis screening in pregnant women leads to worse birth outcomes: the Syphilis Treatment of Partners (STOP) randomised control trial. <i>Sexual Health</i> , 2020, 17, 214.	0.9	18
54	Estimating the effect of pretreatment loss to follow up on TB associated mortality at public health facilities in Uganda. <i>PLoS ONE</i> , 2020, 15, e0241611.	2.5	11

#	ARTICLE	IF	CITATIONS
55	Antimicrobial Resistance of <i>Neisseria Gonorrhoeae</i> in a Newly Implemented Surveillance Program in Uganda: Surveillance Report. <i>JMIR Public Health and Surveillance</i> , 2020, 6, e17009.	2.6	14
56	A new vision for bioethics training in global health. <i>The Lancet Global Health</i> , 2019, 7, e1002-e1003.	6.3	3
57	Anti-retroviral therapy scale-up and its impact on sex-stratified tuberculosis notification trends in Uganda. <i>Journal of the International AIDS Society</i> , 2019, 22, e25394.	3.0	3
58	Research Capacity Strengthening in Sub-Saharan Africa: Recognizing the Importance of Local Partnerships in Designing and Disseminating HIV Implementation Science to Reach the 90-90-90 Goals. <i>AIDS and Behavior</i> , 2019, 23, 206-213.	2.7	6
59	Users beware! Biological variation in complete blood counts over short time intervals. <i>BMJ Evidence-Based Medicine</i> , 2019, 24, 207-208.	3.5	0
60	Rapid antiretroviral therapy initiation in low- and middle-income countries: A resource-based approach. <i>PLoS Medicine</i> , 2019, 16, e1002723.	8.4	16
61	Perspectives on male partner notification and treatment for syphilis among antenatal women and their partners in Kampala and Wakiso districts, Uganda. <i>BMC Infectious Diseases</i> , 2019, 19, 124.	2.9	14
62	Reflexive Laboratory-Based Cryptococcal Antigen Screening and Preemptive Fluconazole Therapy for Cryptococcal Antigenemia in HIV-Infected Individuals With CD4 ≤ 100 Cells/ μL : A Stepped-Wedge, Cluster-Randomized Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 182-189.	2.1	35
63	Complete ciprofloxacin resistance in gonococcal isolates in an urban Ugandan clinic: findings from a cross-sectional study. <i>International Journal of STD and AIDS</i> , 2019, 30, 256-263.	1.1	11
64	Point-of-care diagnostics: needs of African health care workers and their role combating global antimicrobial resistance. <i>International Journal of STD and AIDS</i> , 2019, 30, 404-410.	1.1	9
65	Infectious Diseases Physicians: Improving and Protecting the Public's Health: Why Equitable Compensation Is Critical. <i>Clinical Infectious Diseases</i> , 2019, 69, 352-356.	5.8	15
66	Mentorship and Ethics in Global Health: Fostering Scientific Integrity and Responsible Conduct of Research. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 100, 42-47.	1.4	22
67	Delayed Sputum Culture Conversion in Tuberculosis-Human Immunodeficiency Virus-Coinfected Patients With Low Isoniazid and Rifampicin Concentrations. <i>Clinical Infectious Diseases</i> , 2018, 67, 708-716.	5.8	34
68	Synergistic Impact of Training Followed by On-Site Support on HIV Clinical Practice: A Mixed-Design Study in Uganda With Pre/Post and Cluster-Randomized Trial Components. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 467-475.	2.1	4
69	Performance of loop-mediated isothermal amplification assay in the diagnosis of pulmonary tuberculosis in a high prevalence TB/HIV rural setting in Uganda. <i>BMC Infectious Diseases</i> , 2018, 18, 87.	2.9	19
70	The utility of pharmacokinetic studies for the evaluation of exposure-response relationships for standard dose anti-tuberculosis drugs. <i>Tuberculosis</i> , 2018, 108, 77-82.	1.9	14
71	Effect of TB/HIV Integration on TB and HIV Indicators in Rural Ugandan Health Facilities. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 605-611.	2.1	11
72	A Cross-Cutting Approach to Surveillance and Laboratory Capacity as a Platform to Improve Health Security in Uganda. <i>Health Security</i> , 2018, 16, S-76-S-86.	1.8	21

#	ARTICLE	IF	CITATIONS
73	Brief Report: Pulmonary Tuberculosis Is Associated With Persistent Systemic Inflammation and Decreased HIV-1 Reservoir Markers in Coinfected Ugandans. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 79, 407-411.	2.1	8
74	Academic promotion policies and equity in global health collaborations. <i>Lancet</i> , The, 2018, 392, 1607-1609.	13.7	46
75	The wide utility of rabbits as models of human diseases. <i>Experimental and Molecular Medicine</i> , 2018, 50, 1-10.	7.7	103
76	“Tuberculosis in advanced HIV infection is associated with increased expression of IFN γ and its downstream targets” <i>BMC Infectious Diseases</i> , 2018, 18, 220.	2.9	18
77	Group Mentorship Model to Enhance the Efficiency and Productivity of PhD Research Training in Sub-Saharan Africa. <i>Annals of Global Health</i> , 2018, 84, 170.	2.0	15
78	Vector-Borne Disease is a Common Cause of Hospitalized Febrile Illness in India. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 98, 1526-1533.	1.4	9
79	Immune Reconstitution Inflammatory Syndrome (IRIS): What pathologists should know. <i>Seminars in Diagnostic Pathology</i> , 2017, 34, 340-351.	1.5	20
80	Treatment decisions and mortality in HIV-positive presumptive smear-negative TB in the Xpert ® MTB/RIF era: a cohort study. <i>BMC Infectious Diseases</i> , 2017, 17, 433.	2.9	10
81	Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women. <i>Annals of Internal Medicine</i> , 2017, 167, 384.	3.9	29
82	Cost-effectiveness of CRAG-LFA screening for cryptococcal meningitis among people living with HIV in Uganda. <i>BMC Infectious Diseases</i> , 2017, 17, 225.	2.9	25
83	P1.05...Current use and perceived obstacles to use of point-of-care tests in sub-saharan africa. , 2017, , .		0
84	High-Level <i>Neisseria gonorrhoea</i> Resistance Detected in a Newly Implemented Surveillance Program in Kampala, Uganda. <i>Open Forum Infectious Diseases</i> , 2017, 4, S103-S103.	0.9	0
85	Antimicrobial Resistance of Sterile Site Infections in Sub-Saharan Africa: A Systematic Review. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx209.	0.9	14
86	Reducing Uncertainty for Acute Febrile Illness in Resource-Limited Settings: The Current Diagnostic Landscape. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 96, 1285-1295.	1.4	13
87	Training tomorrow’s leaders in global health: impact of the Afya Bora Consortium Fellowship on the careers of its alumni. <i>BMC Medical Education</i> , 2016, 16, 241.	2.4	15
88	Accelerating the Uptake and Timing of Antiretroviral Therapy Initiation in Sub-Saharan Africa: An Operations Research Agenda. <i>PLoS Medicine</i> , 2016, 13, e1002106.	8.4	34
89	Effect of On-Site Support on Laboratory Practice for Human Immunodeficiency Virus, Tuberculosis, and Malaria Testing. <i>American Journal of Clinical Pathology</i> , 2016, 146, 469-477.	0.7	6
90	Prevention of Early Mortality by Presumptive Tuberculosis Therapy Study: An Open Label, Randomized Controlled Trial. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 95, 1265-1271.	1.4	11

#	ARTICLE	IF	CITATIONS
91	Reply to "A Word of Caution in Considering the Use of the Lipoarabinomannan Lateral Flow Assay on Cerebrospinal Fluid for Detection of Tuberculous Meningitis". <i>Journal of Clinical Microbiology</i> , 2016, 54, 243-243.	3.9	3
92	Vitamin-D deficiency impairs CD4+T-cell count recovery rate in HIV-positive adults on highly active antiretroviral therapy: A longitudinal study. <i>Clinical Nutrition</i> , 2016, 35, 1110-1117.	5.0	33
93	Prevalence and predictors of prior antibacterial use among patients presenting to hospitals in Northern Uganda. <i>BMC Pharmacology & Toxicology</i> , 2015, 16, 26.	2.4	9
94	Is Urinary Lipoarabinomannan the Result of Renal Tuberculosis? Assessment of the Renal Histology in an Autopsy Cohort of Ugandan HIV-Infected Adults. <i>PLoS ONE</i> , 2015, 10, e0123323.	2.5	36
95	High Genotypic Discordance of Concurrent <i>Mycobacterium tuberculosis</i> Isolates from Sputum and Blood of HIV-Infected Individuals. <i>PLoS ONE</i> , 2015, 10, e0132581.	2.5	15
96	Rapid Improvement in Passive Tuberculosis Case Detection and Tuberculosis Treatment Outcomes After Implementation of a Bundled Laboratory Diagnostic and On-Site Training Intervention Targeting Mid-Level Providers. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv030.	0.9	17
97	Predictors and outcomes of mycobacteremia among HIV-infected smear-negative presumptive tuberculosis patients in Uganda. <i>BMC Infectious Diseases</i> , 2015, 15, 62.	2.9	35
98	Population-level tuberculosis incidence in the ART era. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 997-998.	9.1	0
99	Improving the Sensitivity of the Xpert MTB/RIF Assay on Sputum Pellets by Decreasing the Amount of Added Sample Reagent: a Laboratory and Clinical Evaluation. <i>Journal of Clinical Microbiology</i> , 2015, 53, 1258-1263.	3.9	4
100	Integration of antenatal syphilis screening in an urban HIV clinic: a feasibility study. <i>BMC Infectious Diseases</i> , 2015, 15, 15.	2.9	24
101	The effect of standard dose multivitamin supplementation on disease progression in HIV-infected adults initiating HAART: a randomized double blind placebo-controlled trial in Uganda. <i>BMC Infectious Diseases</i> , 2015, 15, 348.	2.9	11
102	Accuracy of Lipoarabinomannan and Xpert MTB/RIF Testing in Cerebrospinal Fluid To Diagnose Tuberculous Meningitis in an Autopsy Cohort of HIV-Infected Adults. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2667-2673.	3.9	27
103	Predictors for MTB Culture-Positivity among HIV-Infected Smear-Negative Presumptive Tuberculosis Patients in Uganda: Application of New Tuberculosis Diagnostic Technology. <i>PLoS ONE</i> , 2015, 10, e0133756.	2.5	11
104	Effect of Educational Outreach Timing and Duration on Facility Performance for Infectious Disease Care in Uganda: A Trial with Pre-Post and Cluster Randomized Controlled Components. <i>PLoS ONE</i> , 2015, 10, e0136966.	2.5	1
105	Multi-media Educational Tool Increases Knowledge of Clinical Trials in Uganda. <i>Journal of Clinical Research & Bioethics</i> , 2014, 05, 165.	0.2	11
106	Association of testosterone levels with socio-demographic characteristics in a sample of Ugandan men. <i>African Health Sciences</i> , 2014, 14, 348.	0.7	3
107	Practice of percutaneous needle autopsy; a descriptive study reporting experiences from Uganda. <i>BMC Clinical Pathology</i> , 2014, 14, 44.	1.8	20
108	Diagnostic Accuracy of a Rapid Urine Lipoarabinomannan Test for Tuberculosis in HIV-Infected Adults. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 270-279.	2.1	70

#	ARTICLE	IF	CITATIONS
109	Optimisation of the Medical Education Partnership Initiative to address African health-care challenges. <i>The Lancet Global Health</i> , 2014, 2, e392.	6.3	9
110	Prospective Cross-Sectional Evaluation of the Small Membrane Filtration Method for Diagnosis of Pulmonary Tuberculosis. <i>Journal of Clinical Microbiology</i> , 2014, 52, 2513-2520.	3.9	10
111	Timing of Antiretroviral Therapy after Diagnosis of Cryptococcal Meningitis. <i>New England Journal of Medicine</i> , 2014, 370, 2487-2498.	27.0	387
112	Point-of-Care Lateral Flow Assays for Tuberculosis and Cryptococcal Antigenuria Predict Death in HIV Infected Adults in Uganda. <i>PLoS ONE</i> , 2014, 9, e101459.	2.5	44
113	Clinical Utility of a Novel Molecular Assay in Various Combination Strategies with Existing Methods for Diagnosis of HIV-Related Tuberculosis in Uganda. <i>PLoS ONE</i> , 2014, 9, e107595.	2.5	8
114	Among Patients with Sustained Viral Suppression in a Resource-Limited Setting, CD4 Gains Are Continuous Although Gender-Based Differences Occur. <i>PLoS ONE</i> , 2013, 8, e73190.	2.5	11
115	Comparison of Methods for Correction of Mortality Estimates for Loss to Follow-Up after ART Initiation: A Case of the Infectious Diseases Institute, Uganda. <i>PLoS ONE</i> , 2013, 8, e83524.	2.5	21
116	Evaluation of Portable Point-of-Care CD4 Counter with High Sensitivity for Detecting Patients Eligible for Antiretroviral Therapy. <i>PLoS ONE</i> , 2012, 7, e34319.	2.5	50
117	Rifampicin for Continuation Phase Tuberculosis Treatment in Uganda: A Cost-Effectiveness Analysis. <i>PLoS ONE</i> , 2012, 7, e39187.	2.5	11
118	Evaluation of WHO Criteria for Viral Failure in Patients on Antiretroviral Treatment in Resource-Limited Settings. <i>AIDS Research and Treatment</i> , 2011, 2011, 1-6.	0.7	16
119	Developing independent investigators for clinical research relevant for Africa. <i>Health Research Policy and Systems</i> , 2011, 9, 44.	2.8	29
120	High rate of misclassification of treatment failure based on WHO immunological criteria. <i>Aids</i> , 2009, 23, 1295-1296.	2.2	12
121	Resurrecting the Triple Threat: Academic Social Responsibility in the Context of Global Health Research. <i>Clinical Infectious Diseases</i> , 2009, 48, 1420-1422.	5.8	21
122	Cause-specific Mortality and the Contribution of Immune Reconstitution Inflammatory Syndrome in the First 3 Years after Antiretroviral Therapy Initiation in an Urban African Cohort. <i>Clinical Infectious Diseases</i> , 2009, 49, 965-972.	5.8	116
123	Immune Reconstitution Inflammatory Syndrome. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 46, 456-462.	2.1	174
124	Both <i>Corynebacterium diphtheriae</i> DtxR(E175K) and <i>Mycobacterium tuberculosis</i> IdeR(D177K) Are Dominant Positive Repressors of IdeR-Regulated Genes in <i>M. tuberculosis</i> . <i>Infection and Immunity</i> , 2005, 73, 5988-5994.	2.2	27
125	Different Strains of <i>Mycobacterium tuberculosis</i> Cause Various Spectrums of Disease in the Rabbit Model of Tuberculosis. <i>Infection and Immunity</i> , 2003, 71, 6004-6011.	2.2	136
126	Naturally Attenuated, Orally Administered <i>Mycobacterium microti</i> as a Tuberculosis Vaccine Is Better than Subcutaneous <i>Mycobacterium bovis</i> BCG. <i>Infection and Immunity</i> , 2002, 70, 1566-1570.	2.2	36

#	ARTICLE	IF	CITATIONS
127	Latent Mycobacterium tuberculosis persistence, patience and winning by waiting. Nature Medicine, 2000, 6, 1327-1329.	30.7	244
128	Conditional Sigma Factor Expression, Using the Inducible Acetamidase Promoter, Reveals that the <i>Mycobacterium tuberculosis sigF</i> Gene Modulates Expression of the 16-Kilodalton Alpha-Crystallin Homologue. Journal of Bacteriology, 1999, 181, 7629-7633.	2.2	35